The company has over 20 years’ experience of research & development into Buffered Hypochlorite based Technology, develop products that do not affect healthy tissue. Our unique hypochlorite technology is the common platform of all RLS Global’s products. Even though the products are tailored to each clinical area, it is the same technology that makes this method of treatment particularly effective.

The benefits with the Unique Hypochlorite technology are:

• Softening damaged or dead tissue, making it easier to remove – a gentle approach to save healthy tissue
• Working without having an effect on healthy tissue
• Chemo-Mechanical Debridement with Antimicrobial Properties

Based on our experience from removing devitalized tissue for caries removal we have developed a new innovative solution, ChloraSolv for Infected Chronic Diabetic Foot Ulcers in need of debridement. Hard to heal wounds is a serious and costly complication of underlying diseases such as diabetes, venous insufficiency or injuries to the skin such as pressure ulcers. Patients suffering from these wounds often experience pain, bad smell, decreased mobility and other problems which seriously affecting the quality of life.

Our overall goal is to provide a gentle and effective debridement method that result in improved care for healthcare professionals reducing the suffering for patients and the overall cost for the society in treating complicated wounds. RLS will initiate pre-clinical activities with the aim of broadening the product portfolio in areas such as burns and clinical indications outside Advance Wound Care during 2020.

The R&D activities are based on the RLS Global’s Unique Buffered Hypochlorite Technology which has a unique property that softens damaged or dead tissue, regardless of whether the application is dental or the treatment of wounds. Once the product has been allowed to act for a few minutes, the damaged or dead tissue can be removed. This creates the conditions that allow the healing process to begin. With regards to dental care specifically, it is important that all the caries is removed, otherwise the problem will recur.

For chronic wounds, the clinical trial that was conducted at Sahlgrenska University Hospital in 2015 has shown that ChloraSolv is most successful when used in the initial treatment. The results of the trial were published the following year in the medical journal Clinical Diabetes and Endocrinology. The positive effects of products based on hypochlorite are well documented. In Sweden, one further, more extensive trial of ChloraSolv has begun in 2019. This involves 55 patients and more applications than the trial at Sahlgrenska. In addition to diabetic foot ulcers, this multi-center trial is also investigating chronic venous and arterial leg ulcers.

One further characteristic of RLS Global’s products is that they are minimally invasive. This means that the treatment methods result in a gentler and less painful treatment than many other methods. ChloraSolv is used by applying the product to the wound. It allows to work for a couple of minutes, after which softened dead and infected tissue can be removed mechanically. The wound is thereby cleaned in an effective and gentle way and is covered with a suitable dressing.

Now that ChloraSolv is certified, an exciting future wait for RLS Global. The fact that the incidence of diabetes is increasing in all countries means that more and more people will suffer problems with chronic wounds. The number of diabetics has increased from 150 million in 1980 to over 425 million in 2017¹. In the industrialized countries, the cost of treating chronic wounds is 2–3 per cent of the total healthcare budget².  When ChloraSolv becomes the natural choice when treating chronic wounds, diabetes patients will be saved a great deal of suffering and will make a contribution to reducing healthcare costs.